Is it possible to do real-time analysis of aggregates in downstream protein solutions?

4 May 2022
Technology Strategy

Eighteen BioPhorum Technology Roadmapping Phorum members (eleven end-users and seven supply partners) have joined forces to collaborate on a hands-on downstream proof of concept (POC) project. The practical POC work has just begun at Merck KGaA (Healthcare)’s Corsier-sur-Vevey site in Switzerland and will investigate the real-time analysis of aggregates content in protein solutions during the bind/elute cation exchange step of a mAb process. It will use multi-angle light scattering (MALS) analytical technology provided by Wyatt Technology.

Bind/elute cation exchange chromatography is typically used to control aggregates when purifying monoclonal antibodies. However, current pooling strategies are UV- or volume-based and not triggered by real-time measurements against critical quality attribute thresholds.

These strategies may result in yield and quality variations of the pools and need a safety margin built into the UV-based collection to maintain product quality. However, this leads to sub-optimal yields, which could be improved if the pooling was based on a real-time aggregate breakthrough.

As this is a common strategy for aggregate removal, demonstrating the benefits of pooling using a critical quality attribute rather than a conservative UV threshold is attractive to many companies. It has significant potential for increased process yields, fewer deviations and improved consistency of input to subsequent process steps, all resulting in a reduced cost of goods.

“We expect aggregate monitoring and control to be critical for many of our processes,” said Jonathan Souquet, Global Head of Process Sciences at Merck KGaA (Healthcare). “I expect that if the POC and implementation cycle of this technology by Merck were successful, it would be applied to a number of our processes, facilities, and production lines. Once the technology and capability are built into our development and production infrastructure, it can also be applied for different applications.”

Souquet added, “The path to implementing process analytical techniques beyond exploration and innovation has been limited to date, and the way this project has been structured has its sights on the value-generating implementation pathway.”

The project is a great example of how BioPhorum can help members and industry by gathering a team of world-class, multi-disciplinary experts to devise a solution and facilitate the actual development of a piece of technology. Participating member companies have designed the experimental studies, will jointly analyze the results, collaborate on tackling challenges, and ensure an industry-wide solution instead of an ‘n of 1’.

Moira Lynch, Senior Innovation Leader at Thermo Fisher Scientific, explained that the collaboration had significant benefits. “Technology providers like us often partner with their customers, but this is typically a one-to-one situation. BioPhorum provides a safe space for industry to speak openly about challenges and find solutions together. The broad perspectives included in the discussions make for more robust solutions.”

Gunnar Malmquist, Senior Principal Scientist at Cytiva, added that “the real value of BioPhorum’s approach is bringing together a team that has different resources such as the process understanding, availability of feed material, an opportunity to run the experiments, and someone who understands the analytical aspects. We know that it can be difficult to successfully bring all these elements together at the same time as a single company.”

Carrie Mason, Associate Director of Process Science and Technology R&D at Lonza, said that this activity could happen outside of BioPhorum, but it would not be simple. “I think the headwinds would be very strong. As a CDMO, we might not have the same weight behind us as companies with much larger R&D budgets that could have more influence with a vendor. The advantage with BioPhorumis that it levels the playing field so that even small or medium-sized biotechs or CDMOs can be influential.”

Building a POC using real-time MALS would create a game-changing process analytical tool, but what would the next steps be?

“If we see broad acceptance and the cost benefits of developing comparable process analytical technology (PAT) products for full-scale manufacturing turn out to be favorable, we will need to get to work developing them,” said Geofrey Wyatt, CEO of Wyatt Technology, whose company is providing the MALS technology for the POC project.

Mason added that it was tough to estimate the effect on implementation timescales, but “a new piece of kit that doesn’t tick all the technology readiness indicators might take two or three years before it’s in the development phase. If a technology created by collaboration already answers the feasibility questions, then development might mean it’s only 6–12 months before it would be ready to go to the next stage, e.g., a rollout in a GMP environment.”

With so many benefits, the POC project can be a giant step-change for industry, with collaboration at its heart. “The BioPhorum technology roadmap is reaching a consensus on the requirements for a novel technology that will benefit the entire industry, said Wyatt. “Added to this is working with vendors with unique capabilities to realize and implement that technology. This all holds a lot of promise for every contributing member.”

A major milestone – a harmonized approach to product carbon footprint data
Combination products – MediPhorum’s ‘state of the nation’ report
Inaugural BioPhorum Quality face to face – get involved
Forecasting the demand for single-use systems
The new Drug Substance Strategic Value Framework – addressing industry pain points

Advanced Therapy Medicinal Products

Advanced Therapy Medicinal Products support the quest for better and faster development of cell, gene and RNA therapies​ through connecting therapy developers, contract manufacturing, and testing organizations to gain an understanding and respond to the challenges faced by the advanced therapeutics industry.

Development Group

Development Group accelerates and improves the development process of biopharmaceutical medicines for the benefit of the patient. Replacing isolation with collaboration by providing a “safe” space where subject matter experts can work on sharing solutions and best practice on emerging industry trends, implementation of new technologies and common issues whilst ensuring their intellectual property and confidentiality is protected.

Drug Substance

Drug Substance advances excellence in drug substance manufacturing and testing, acting as an industry voice to accelerate technology adoption, implement post-approval change more rapidly and increase confidence in maintaining compliance.

Fill Finish

Fill Finish accelerates development and acceptance of sustainable world-class filling and packaging operations for drug product which meets the future needs of patients. Through innovative solutions resulting from the sharing of expertise, we can overcome common performance challenges and deliver on quality and regulatory compliance.

Information Technology

Information Technology accelerates digital maturity across the ​global pharmaceutical manufacturing industry.


BioPhorum Quality provides a dedicated, safe space for quality professionals from biomanufacturers and contract organizations to coalesce and enhance effective collaboration to address shared industry challenges.


Regulatory CMC brings leaders together who have a common goal – to improve access to medicines through innovation in the Regulatory ecosystem. It provides a dedicated space for strategic leadership and a coordinated industry voice, to move from divergence to convergence.

Supply Chain to Patient

Supply Chain to Patient transforms the performance of global pharmaceutical clinical and commercial outbound supply chains through industry collaboration by creating transparent patient-centric, resilient and agile E2E supply chains, that consistently deliver high-quality medicines ensuring an uninterrupted supply to patients.

Supply Partner

Supply Partner is a trusted advisory group and collaboration that is the engine for driving change across the global industry for all things relevant to the inbound supply chain. Addressing the challenges of complexity, resilience, cost, sustainability, and innovation.


Sustainability enables the industry’s transition to a low carbon, circular future – supporting members to improve patient health while respecting the planet. We activate multi-disciplinary teams drawn from our network to deliver environmental sustainability improvements across the value chain.

Technology Strategy

Technology Strategy acts as one voice of the industry to define strategy, accelerate technology transformation and support technology translation and adoption. With a purpose of enabling the future state of flexible, resilient, sustainable end-to-end biomanufacturing.

An industry perspective on understanding AAV capsid content variants
Needle On Yellow Background
An intercompany perspective on practical experiences of predicting, optimizing and analyzing high concentration biologic therapeutic formulations
The Drug Substance 2.0 Strategic Value Framework
Coloured dots on teal, next to vial
BioPhorum’s holistic approach to container closure integrity
Magnifying glass over a tablet all coloured blue
Digital Plant Maturity Model 3.0
Investigation Digital Workstreams
Peer to peer practical guidance on remote inspections and audits
The next step in building regulatory as a capability to enable strategic innovation across the BioPhorum community
BioPhorum roundals on sugical gloves
A visionary strategic framework for future patient-centric outbound biopharmaceutical supply chains
DNA and Earth on blue background
A vision for the biopharmaceutical industry’s inbound supply chain
Lightbulb And Icons On Colourful Background
BioPhorum environmental sustainability roadmap 2022
Technology Roadmap V 2.0
BioPhorum Technology Roadmapping roadmap vision 2.0


Documents including best practices, vision statements and peer reviewed papers to help you take value back to your business.


Discussing all aspects of the biopharmaceutical industry, from digitization and knowledge management to raw materials, supply chain, sustainability and more. Learn from the perspectives of those at the forefront of the industry.


BioPhorum Connect is our podcast series that keeps you up to date with the latest news and trends in the biopharmaceutical industry. From experienced professionals to thought leaders, these podcasts bring you the insights and perspectives of experts from around the world.


A variety of resources including design tools and user requirement specifications to help you improve and streamline your business processes.

Benchmarks and Surveys

Research conducted among the BioPhorum membership providing evidence to support change and identify best practice.

Browse all

Access a variety of free tools and papers and other resources designed to provide you with up-to-date information and insights to help you make informed decisions and maximize your success. Access our resources today and start making improving and streamlining your business processes.

Bioreactivity testing in single-use system biomanufacturing
Bioreactivity testing in single-use system biomanufacturing
Bioreactivity testing in single-use system biomanufacturing
Magnifying glass over a tablet all coloured blue
Digital Plant Maturity Model 3.0
Bioreactivity testing in single-use system biomanufacturing